Guardant Health Eyes Earlier Breakeven As Liquid Biopsy Boosts Outlook
Lab Test Innovator Focuses On US Coverage Gaps
Guardant Health expects to breakeven by 2028. A positive pricing outlook for the Guardant 360 lab test could bring this forward by maybe one year, CFO Mike Bell told the Jefferies London Healthcare Conference.
